Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact

Sánchez Martínez, Domingo Antonio; Salas Lucia, Federico; Jiang, Hanzi; Ruiz-Carreño, Paula; Alonso Romero, José Luis

Publication:
Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact

dc.contributor.author	Sánchez Martínez, Domingo Antonio
dc.contributor.author	Salas Lucia, Federico
dc.contributor.author	Jiang, Hanzi
dc.contributor.author	Ruiz-Carreño, Paula
dc.contributor.author	Alonso Romero, José Luis
dc.contributor.department	Medicina
dc.date.accessioned	2024-11-05T11:42:56Z
dc.date.available	2024-11-05T11:42:56Z
dc.date.issued	2022-07-26
dc.description	© The Author(s) 2022. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/ This document is the Published version of a Published Work that appeared in final form in BMC Health Services Research. To access the final edited and published work see https://doi.org/10.1186/s12913-022-08222-9
dc.description.abstract	Objective Analyze the cost contributors and their impact on the drug cost avoidance (DCA) resulting from cancer clinical trials over the period of 2015–2020 in a tertiary-level hospital in Spain (HCUVA). Methods We performed a cross-sectional, observational, retrospective study of a total of 53 clinical trials with 363 patients enrolled. We calculated the DCA from the price of the best standard of care (i.e.: drugs that the institution would otherwise fund). A linear regression model was used to determine cost contributors and estimate their impact. Results The total DCA was ~ 4.9 million euros (31 clinical trials; 177 enrollees), representing ~ 30% and ~ 0,05% approximately of the annual pharmaceutical expenditures at the HCUVA and for the Spanish Health System, respectively. Cancer type analysis showed that lung cancer had the highest average DCA by trial, indicating that treatments in these trials were the most expensive. Linear regression analysis showed that the number of patients in a trial did not significantly affect that trial's DCA. Instead, cancer type, phase trials, and intention of treatment were significant cost contributors to DCA. Compared to digestive cancer trials, breast and lung trials were significantly more expensive, (p < 0.05 and p < 0.1, respectively). Phase III trials were more expensive than Phase II (p < 0.01) and adjuvant trials were less expensive than palliative (p < 0.05). Conclusion We studied cost contributors that significantly impacted the estimated DCA from cancer clinical trials. Our work provides the groundwork to explore DCA contributors with potential to enhance public relations material and serve as a negotiating tool for budgeting, thus playing an important role to inform decisions about resource allocation.	es
dc.format	application/pdf	es
dc.format.extent	7	es
dc.identifier.doi	https://doi.org/10.1186/s12913-022-08222-9
dc.identifier.eisbn	BMC Health Services Research, 2022, Vol. 22: 948	es
dc.identifier.issn	Electronic: 1472-6963
dc.identifier.uri	http://hdl.handle.net/10201/146003
dc.language	eng	es
dc.publisher	BioMed Central
dc.relation	Sin financiación externa a la Universidad	es
dc.relation.publisherversion	https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-022-08222-9
dc.rights	info:eu-repo/semantics/openAccess	es
dc.rights	Atribución 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.subject	Hospital management	es
dc.subject	Linear regression	es
dc.subject	Healthcare costs	es
dc.subject	Sustainability	es
dc.subject	Clinical Trials	es
dc.subject	Oncology	es
dc.title	Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact	es
dc.type	info:eu-repo/semantics/article	es
dspace.entity.type	Publication	es